Mechanisms and Refinements of PSCA Directed Antibody Therapy

Abstract

PSCA is a cell surface antigen expressed by a majority of prostate, bladder and pancreatic cancers. An antibody against PSCA has preclinical activity against prostate cancer xenografts. The mechanism of this activity is not known. The goals of this project include 1) determining whether anti-tumor activity is Fc-region dependent or independent (or both) and 2) testing combination therapies to identify potential synergies or antagonisms that may be relevant to the clinic. We have also proposed to develop humanized antibodies for potential translation to the clinic.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2003
Accession Number
ADA413309

Entities

People

  • Robert E. Reiter

Organizations

  • University of California, Los Angeles

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Antibodies
  • Antigens
  • Biomedical Research
  • Biomolecules
  • California
  • Cancer
  • Cells
  • Chemical Compounds
  • Combination Therapy
  • Electronic Mail
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Stem Cells
  • Therapy

Fields of Study

  • Biology
  • Medicine

Readers

  • Housing Policy Studies in Military Families with Privatization and Telomerase Allowance Units, Multi-Family Housing, and Telomere Lengths.
  • Oncology
  • Prostate Cancer Biology.